NasdaqHealth CarePharmaceutical PreparationsWALTHAM, MA

Q32 Bio Inc. QTTB

Ask your AI

Estimated market cap $260.64M29.92M shares, shares as of Oct 31, 2026CIK 1661998

Insider trades, 12 mo

4 buys · 8 sells

$459.7K sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

31.5% of shares · 14 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Q32 Bio Inc.'s latest quarterly report, compared with the one before.

Filed Nov 4, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Q32 Bio Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

12 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Aug 25, 2026. Insiders have two business days to file.

Recent insider trades

Lee Kalowski CFO and President	Aug 25 Form 4 ↗	Sale	−$65.8K 3,972 sh @ $16.56	-45.1%
Jodie Pope Morrison CEO, Director	Aug 25 Form 4 ↗	Sale	−$163.0K 9,845 sh @ $16.56	-45.1%
Shelia M. Violette Chief Scientific Officer	Aug 25 Form 4 ↗	Sale	−$46.3K 2,798 sh @ $16.56	-45.1%
Diyong Xu Director, 10% owner	May 28 Form 4 ↗	Buy	+$5.0M 625,000 sh @ $8.00	-15.5%
Diyong Xu Director, 10% owner	May 28 Form 4 ↗	Buy	+$10.0M 1.25M sh @ $8.00	-15.5%

All QTTB insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

9.42M shares

61 funds report QTTB. Values checked against market prices.

Funds own 75% of shares (Q2 2026)

72 funds hold the stock.

Q3 2026: 31% · 5,560 of ~8,900 funds reported so far

Q2 202574%
Q3 202569%
Q4 202555%
Q1 202664%
Q2 202675%
Q3 2026 (so far)31%

Q3 2026. 27 new, 14 added to, 8 trimmed, 37 exited since Q2 2026.

Top 13F holders
#
1	Atlas Venture Life Science Advisors, LLC 13F ↗	2.72M	$22.5M	unchanged
2	JPMorgan Chase & Co 13F ↗	1.06M	$10.1M	New
3	Vanguard Capital Management LLC 13F ↗	1.01M	$8.3M	+94.4%
4	American Century Companies Inc 13F ↗	652,597	$5.4M	+139.3%
5	Qube Research & Technologies Ltd 13F ↗	381,469	$3.2M	New
6	Marshall Wace, LLP 13F ↗	368,935	$3.1M	+450.3%
7	BlackRock, Inc. 13F ↗	340,353	$2.8M	+187.2%
8	Aberdeen Group plc 13F ↗	302,500	$2.5M	New
9	Sanofi 13F ↗	244,083	$2.0M	unchanged
10	Geode Capital Management, LLC 13F ↗	240,954	$2.0M	+96.4%

Download CSV Every fund that holds QTTB, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Q32 Bio Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Q32 Bio Inc. and its lobbying firms report each quarter.

Loading…

H-1B labor applications at Q32 Bio Inc.

0 certified in 12 mo

Labor condition applications decided by the Department of Labor, matched to Q32 Bio Inc. by employer name. An application is not a hire.

Median yearly wage offered, full-time certified applications, Jul 2025 to Jun 2026: —

H-1B labor applications decided at Q32 Bio Inc. by quarter
Quarter	Certified	All decided	Workers asked for
2024 Q3	0	0	0
2024 Q4	0	0	0
2025 Q1	0	0	0
2025 Q2	0	1	0
2025 Q3	0	0	0
2025 Q4	0	0	0
2026 Q1	0	0	0
2026 Q2	0	0	0

All QTTB applications

We match the employer's name to a public company automatically, including a reviewed list of subsidiaries. A subsidiary can be missed and a similar name can be matched wrongly. The files carry no worker names.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q1 2024	38	—	7.43M	$125.9M
Q2 2024	54	+16	8.07M	$144.2M
Q3 2024	73	+19	9.11M	$406.0M
Q4 2024	92	+19	11.00M	$37.8M
Q1 2025	73	-19	9.41M	$15.5M
Q2 2025	61	-12	8.98M	$13.4M
Q3 2025	53	-8	8.43M	$16.6M
Q4 2025	52	-1	8.04M	$26.7M
Q1 2026	53	+1	9.43M	$60.6M
Q2 2026	72	+19	22.21M	$282.9M
Q3 2026	61	-11	9.42M	$79.5M

Each point is a quarter-end, from Q1 2024 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (746964105). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q1 2024) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes22 in 12 mo 8-K events3 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesForm 144 · 2 in 12 mo Executive pay3 fiscal years Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials2 active IPO history2 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Q32 Bio Inc.
Address: 830 WINTER STREET, WALTHAM, MA 02451
Phone: 781-999-0232
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: DE
Listed as: QTTB (Nasdaq)
Former names: Q32 Bio Inc. (until 2026); Homology Medicines, Inc. (until 2024)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$8.71−$0.11 (−1.25%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $7.52 · High $9.34Nov 13, 2026

Aug 13, 2026Low $7.52 · High $16.36Nov 13, 2026

Nov 13, 2025Low $1.93 · High $21.38Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.